ATE538805T1 - Fgf-varianten und anwendungsverfahren dafür - Google Patents

Fgf-varianten und anwendungsverfahren dafür

Info

Publication number
ATE538805T1
ATE538805T1 AT03720833T AT03720833T ATE538805T1 AT E538805 T1 ATE538805 T1 AT E538805T1 AT 03720833 T AT03720833 T AT 03720833T AT 03720833 T AT03720833 T AT 03720833T AT E538805 T1 ATE538805 T1 AT E538805T1
Authority
AT
Austria
Prior art keywords
fgf
beta
amino acid
individual
variant
Prior art date
Application number
AT03720833T
Other languages
English (en)
Inventor
Oren Bogin
Avner Yayon
Original Assignee
Prochon Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prochon Biotech Ltd filed Critical Prochon Biotech Ltd
Application granted granted Critical
Publication of ATE538805T1 publication Critical patent/ATE538805T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03720833T 2002-05-09 2003-05-09 Fgf-varianten und anwendungsverfahren dafür ATE538805T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14956202A IL149562A0 (en) 2002-05-09 2002-05-09 Fgf variants and methods for use thereof
PCT/IL2003/000379 WO2003094835A2 (en) 2002-05-09 2003-05-09 Fgf variants and methods for use thereof

Publications (1)

Publication Number Publication Date
ATE538805T1 true ATE538805T1 (de) 2012-01-15

Family

ID=28460400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720833T ATE538805T1 (de) 2002-05-09 2003-05-09 Fgf-varianten und anwendungsverfahren dafür

Country Status (9)

Country Link
US (6) US7563769B2 (de)
EP (1) EP1572080B1 (de)
AT (1) ATE538805T1 (de)
AU (1) AU2003224406A1 (de)
CA (2) CA2483602C (de)
ES (1) ES2378305T3 (de)
IL (3) IL149562A0 (de)
SG (1) SG148037A1 (de)
WO (1) WO2003094835A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
ES2374822T3 (es) * 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
JP2009508596A (ja) 2005-09-19 2009-03-05 ヒストジェニックス コーポレイション 細胞支持基材及びその調製方法
WO2007119240A2 (en) 2006-04-17 2007-10-25 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
EP2083846B1 (de) * 2006-09-28 2015-07-15 Hepacore Ltd. N-terminale fgf-varianten mit erhöhter rezeptor-selektivität und ihre verwendungen
EP2106263B1 (de) 2007-01-04 2016-12-21 Hepacore Ltd. Wasserlösliche und reaktive derivate von carboxy-polysacchariden und fibrinogen-konjugate daraus
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
WO2009111069A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
EP2310039B1 (de) * 2008-05-02 2014-07-16 University Of Western Ontario Fgf-9 und seine anwendung in verbindung mit blutgefässen
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010083051A2 (en) * 2009-01-15 2010-07-22 ProChon Biotech, Ltd. Cartilage particle tissue mixtures optionally combined with a cancellous construct
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2011031642A2 (en) * 2009-09-08 2011-03-17 Musculoskeletal Transplant Foundation Inc. Tissue engineered meniscus repair composition
US20110059178A1 (en) * 2009-09-08 2011-03-10 Musculoskeletal Transplant Foundation Inc. Tissue Engineered Meniscus Repair Composition
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
WO2012038953A2 (en) * 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
EP2853273A4 (de) * 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd Promoter für knochenreparatur
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2930181B1 (de) 2014-04-07 2017-10-11 Miltenyi Biotec GmbH Fibroblast-Wachstumsfaktormuteine mit erhöhter Aktivität
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN104162148A (zh) * 2014-07-17 2014-11-26 中国人民解放军第三军医大学第三附属医院 Fgf9在制备促进骨关节炎软骨修复的药物中的应用
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (de) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa zur behandlung von tracheobronchomalazie
EP3600383A4 (de) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie (hpp) bei erwachsenen und jugendlichen
US11267855B2 (en) * 2018-03-16 2022-03-08 The Board Of Trustees Of The University Of Arkansas Engineered FGF1 and FGF2 compositions and methods of use thereof
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN118101931B (zh) 2019-05-15 2025-02-21 华为技术有限公司 视频译码中用于参考图像重采样的双向光流方法和设备
CN114746436B (zh) * 2019-11-25 2024-07-02 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
CA1260391A (en) 1985-03-28 1989-09-26 Karl A. Piez Xenogeneic collagen/mineral preparations in bone repair
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5859208A (en) 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
DE3826915A1 (de) 1988-08-09 1990-02-15 Henkel Kgaa Neue werkstoffe fuer den knochenersatz und knochen- bzw. prothesenverbund
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5576288A (en) * 1989-04-27 1996-11-19 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5425769A (en) 1990-04-23 1995-06-20 Snyders, Jr.; Robert V. Composition of material for osseous repair
DE69119869T2 (de) 1990-11-23 1996-12-12 American Cyanamid Co Chimeres Fibroblasten-Wachstumsfaktor
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
DE4120325A1 (de) 1991-06-20 1992-12-24 Merck Patent Gmbh Implantatwerkstoff
WO2004083072A1 (ja) 1991-07-31 2004-09-30 Takeo Kumada ペースト状物品のためのディスペンサおよびペースト状物品の押し出し方法
EP0608546A3 (en) * 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
US5491220A (en) * 1993-09-24 1996-02-13 Yeda Research And Development Co., Ltd. Surface loop structural analogues of fibroblast growth factors
US5656598A (en) * 1994-03-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Use of fibroblast growth factors to stimulate bone growth
ES2225840T3 (es) * 1994-03-08 2005-03-16 Osteosa Liquidation Trust Utilizacion de factores de crecimiento de fibroblasto para estimular el crecimiento oseo.
US6110746A (en) 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
IL116477A (en) 1995-12-21 2000-02-29 Hadasit Med Res Service Bone graft substitute and process for producing same
US6221854B1 (en) * 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
EP2339002A1 (de) * 1996-10-16 2011-06-29 ZymoGenetics, Inc. Homologe des Fibroblasten-Wachstumsfaktors
JP4388602B2 (ja) * 1997-02-07 2009-12-24 ストライカー コーポレイション マトリクスを含まない骨形成デバイス、移植片、およびその使用方法
JP4247846B2 (ja) * 1997-07-03 2009-04-02 デュピュイ・スパイン・インコーポレーテッド 架橋ポリサッカリド薬物キャリア
US5998170A (en) * 1997-10-03 1999-12-07 Amgen Inc. Polynucleotides encoding hepatocyte-specific members of the FGF family
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
WO2000047114A1 (en) 1999-02-12 2000-08-17 Collagenesis, Inc. Injectable collagen-based delivery system for bone morphogenic proteins
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
WO2001038357A2 (en) 1999-11-22 2001-05-31 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
AU1804201A (en) 1999-12-02 2001-06-12 Zymogenetics Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
EP1248844B8 (de) * 1999-12-22 2006-10-25 Ortho-McNeil Pharmaceutical, Inc. Analoge des humanen basischen fibroblasten-wachstumsfactors
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
EP1325953A4 (de) * 2000-09-12 2006-03-22 Yukio Kato Methode zur kultivierung von mesenchymalen stammzellen
IL138529A0 (en) 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
EP1397484A4 (de) 2001-03-27 2005-05-25 Massachusetts Inst Technology Verfahren und produkte im zusammenhang mit fgf-dimerisierung
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
EP1444995A1 (de) 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FGF-2-Proteinderivate zur Herstellung von Biomaterialien oder medizinischen Artikeln wie Stents
EP2083846B1 (de) * 2006-09-28 2015-07-15 Hepacore Ltd. N-terminale fgf-varianten mit erhöhter rezeptor-selektivität und ihre verwendungen

Also Published As

Publication number Publication date
US8609823B2 (en) 2013-12-17
EP1572080B1 (de) 2011-12-28
CA2823041C (en) 2018-02-27
CA2483602C (en) 2013-10-15
SG148037A1 (en) 2008-12-31
IL165079A0 (en) 2005-12-18
US8916522B2 (en) 2014-12-23
WO2003094835A2 (en) 2003-11-20
IL149562A0 (en) 2002-11-10
IL165079A (en) 2012-08-30
CA2823041A1 (en) 2003-11-20
EP1572080A4 (de) 2008-06-11
ES2378305T3 (es) 2012-04-11
US20130338070A1 (en) 2013-12-19
IL220726A0 (en) 2012-08-30
US20170095533A1 (en) 2017-04-06
AU2003224406A1 (en) 2003-11-11
US20050148511A1 (en) 2005-07-07
CA2483602A1 (en) 2003-11-20
US7563769B2 (en) 2009-07-21
EP1572080A2 (de) 2005-09-14
US9487568B2 (en) 2016-11-08
US20120214739A1 (en) 2012-08-23
US8119783B2 (en) 2012-02-21
US20090247462A1 (en) 2009-10-01
IL220726A (en) 2017-04-30
WO2003094835A3 (en) 2007-03-08
US20150072426A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
ATE538805T1 (de) Fgf-varianten und anwendungsverfahren dafür
WO1997030085B1 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
DE60327771D1 (de) Glp-1 und behandlungsmethode für diabetes
ATE383168T1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
BR0012200B1 (pt) composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero.
ATE458054T1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
DE602004029038D1 (de) Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
RU2009130434A (ru) Рекомбинантные молекулы лубрицина и их использование
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR0314619A (pt) Análogos de ghrh
DE69938064D1 (de) Aminoterminal modifizierte parathyroidhormon (pth) analoge
DE60138552D1 (de) Peptide mit integrinbindungsmotiv und behandlungsmethoden für muskelkrankheiten
DK1001802T3 (da) Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
BR0305039A (pt) Uso de compostos que possuem a atividade biológica de peptìdeo vasoativo intestinal para o tratamento da sarcoidose
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
PE20030608A1 (es) Composicion y metodo para tratar diabetes
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
BR0206693A (pt) Uso de polifosfato de dinucleosìdeo para estimular remoção de fluido em distúrbios de retina
DE69424657D1 (de) Osteogene wachstums-oligopeptide und diese enthaltende pharmazeutische zusammensetzungen
AU2006206393A1 (en) Methods for treating adhesive capsulitis
BR0312200A (pt) Implante protético composto, processo para a fabricação de um implante protético composto e utilização de um liofilizado como revestimento para um implante protético
BR9612355A (pt) Agentes de ligação com os receptores de ácido hialurÈnico e o uso destes.
EP4401743B1 (de) Zusammensetzung mit natriumhyaluronat und aminosäuren zur verwendung im orthopädischen bereich